Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 3
2011 3
2012 3
2013 4
2014 8
2015 12
2016 12
2017 6
2018 6
2019 9
2020 11
2021 13
2022 21
2023 17
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

115 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis: The RINOMAX Randomized Clinical Trial.
Piehl F, Eriksson-Dufva A, Budzianowska A, Feresiadou A, Hansson W, Hietala MA, Håkansson I, Johansson R, Jons D, Kmezic I, Lindberg C, Lindh J, Lundin F, Nygren I, Punga AR, Press R, Samuelsson K, Sundström P, Wickberg O, Brauner S, Frisell T. Piehl F, et al. Among authors: frisell t. JAMA Neurol. 2022 Nov 1;79(11):1105-1112. doi: 10.1001/jamaneurol.2022.2887. JAMA Neurol. 2022. PMID: 36121672 Free PMC article.
Alping P, Frisell T, Svenningsson A, Piehl F. Alping P, et al. Among authors: frisell t. Ann Neurol. 2016 Nov;80(5):791-792. doi: 10.1002/ana.24767. Epub 2016 Sep 27. Ann Neurol. 2016. PMID: 27553863 No abstract available.
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial.
Svenningsson A, Frisell T, Burman J, Salzer J, Fink K, Hallberg S, Hambraeus J, Axelsson M, Nimer FA, Sundström P, Gunnarsson M, Johansson R, Mellergård J, Rosenstein I, Ayad A, Sjöblom I, Risedal A, de Flon P, Gilland E, Lindeberg J, Shawket F, Piehl F, Lycke J. Svenningsson A, et al. Among authors: frisell t. Lancet Neurol. 2022 Aug;21(8):693-703. doi: 10.1016/S1474-4422(22)00209-5. Lancet Neurol. 2022. PMID: 35841908 Clinical Trial.
Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies.
Luna G, Alping P, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, Hillert J, Langer-Gould A, Lycke J, Nilsson P, Salzer J, Svenningsson A, Vrethem M, Olsson T, Piehl F, Frisell T. Luna G, et al. Among authors: frisell t. JAMA Neurol. 2020 Feb 1;77(2):184-191. doi: 10.1001/jamaneurol.2019.3365. JAMA Neurol. 2020. PMID: 31589278 Free PMC article.
Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study.
Huss V, Bower H, Hellgren K, Frisell T, Askling J; Behalf of the ARTIS group; behalf of the ARTIS group. Huss V, et al. Among authors: frisell t. Ann Rheum Dis. 2023 Jul;82(7):911-919. doi: 10.1136/ard-2022-223636. Epub 2023 Mar 3. Ann Rheum Dis. 2023. PMID: 36868796 Free PMC article.
Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme.
Frisell T, Bower H, Morin M, Baecklund E, Di Giuseppe D, Delcoigne B, Feltelius N, Forsblad-d'Elia H, Lindqvist E, Lindström U, Askling J; ARTIS Study group. Frisell T, et al. Ann Rheum Dis. 2023 May;82(5):601-610. doi: 10.1136/ard-2022-223762. Epub 2023 Feb 14. Ann Rheum Dis. 2023. PMID: 36787994 Free PMC article.
Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis.
Starvaggi Cucuzza C, Longinetti E, Ruffin N, Evertsson B, Kockum I, Jagodic M, Al Nimer F, Frisell T, Piehl F. Starvaggi Cucuzza C, et al. Among authors: frisell t. Neurol Neuroimmunol Neuroinflamm. 2022 Nov 21;10(1):e200056. doi: 10.1212/NXI.0000000000200056. Print 2023 Jan. Neurol Neuroimmunol Neuroinflamm. 2022. PMID: 36411076 Free PMC article.
Genome-wide investigation of persistence with methotrexate treatment in early rheumatoid arthritis.
Sysojev AÖ, Saevarsdottir S, Diaz-Gallo LM, Silberberg GN, Alfredsson L, Klareskog L, Baecklund E, Björkman L, Kastbom A, Rantapää-Dahlqvist S, Turesson C, Jonsdottir I, Stefansson K, Frisell T, Padyukov L, Askling J, Westerlind H. Sysojev AÖ, et al. Among authors: frisell t. Rheumatology (Oxford). 2024 May 2;63(5):1221-1229. doi: 10.1093/rheumatology/kead301. Rheumatology (Oxford). 2024. PMID: 37326842 Free PMC article.
Gender dysphoria in twins: a register-based population study.
Karamanis G, Karalexi M, White R, Frisell T, Isaksson J, Skalkidou A, Papadopoulos FC. Karamanis G, et al. Among authors: frisell t. Sci Rep. 2022 Aug 4;12(1):13439. doi: 10.1038/s41598-022-17749-0. Sci Rep. 2022. PMID: 35927439 Free PMC article.
115 results